Are you T V Fofanova?

Claim your profile

Publications (5)0.47 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim. To evaluate the drug implied to improve the metabolic resistance to stress (adaptogen), Qudesan®, on its influence on cardiovascular system, psychological status and life quality of patients with average to high cardiovascular risk in the extreme climatic conditions (the summer heat). Material and methods. We included 60 patients; for 30 of those the Qudesan® 40 gtts. qd was added to standard drug therapy; other 30 patients were controls. We measured office BP, potassium and sodium concentrations; malonic dialdehyde (MDA), superoxidedysmutase (SOD) in erythrocytes. Then the relation of MDA/SOD was calculate. Patients also completed the questionnaire made up for this study. Results. In the Qudesan® group during the heat period we found lowering of SBP (Δ -13,8 mmHg, p=0,02), DBP (Δ -4,5 mmHg, p=0,05) and PWV (Δ -0,8 m/s, p=0,05) absent in the control. Also in Qudesan® group the concentration of sodium starts to increase during the heat period (Δ +1,0 mM/l, p=0,008). This increase becomes significant by september (Δ +1,7 mM/l, p=0,008) and is probably adaptive. The level of MDA (p<0,05) and MDA/SOD relation, the signs of “antioxydant potential”, in blood were increasing significantly during the summer heat only in control group. The complaints on heart rhythm disorders (p=0,04) and on CHF worsening (p=0,09) after the end of heat period were more common in control group. That is the Qudesan® shows adaptogenic effect and can be used to improve adaptability during the heat period and its switching to cloder time in patients with compensated CVD.
    Russian Journal of Cardiology 01/2015; 109(5):101-108. · 0.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the study was to investigate relationship between the presence of a drug in the list of supplementary drug provision (SDP) and compliance to its consumption by outpatients with arterial hypertension as well as determination of the place of SDP in a row of other factors affecting compliance to treatment. Methods. Patients (men and women) older than 18 years with initial level of office systolic arterial pressure (AP) 140-179 mm Hg and diastolic AP up to 100 mm Hg who visited regional internist. The study was conducted at the base of 82 Moscow polyclinics with participation of 185 physicians and 5474 patients. In all patients besides general clinical examination with office AP measurement calculation of body mass index and assessment of risk factors and concomitant therapy were carried out. All patients assessed themselves their self feeling with the use of visual-analog scale (VAS). Compliance of patients to antihypertensive therapy was evaluated with the help of the Moriski - Green test. Fact of continuous use of antihypertensive drugs received by patients within framework of the SDP system was necessarily obligatory. For final analysis 4816 ambulatory cards were selected. Results. Portion of patients with low compliance to therapy was greatly than that of patients with high compliance to therapy (61.1 vs. 38.9%, respectively, p=0.00001). Inclusion into analysis of additional factor (presence of CHD) reduced contribution of SDP to compliance to 25%, but it remained as before significant (p<0.0007). However addition to these factors of other parameters such as presence of diabetes mellitus or tonometer at home completely leveled effect of SDP on compliance to therapy (p<0.12). Conclusion. Presence of drugs in the SDP list significantly elevates compliance to therapy. However SDP does not appear the only independent predictor of high compliance. If SDP is considered together with other determining factors (presence of concomitant IHD and diabete, readiness to spend money for tonometer) its role as independent factor of high compliance is diminished and loses significance.
    Kardiologiia 01/2011; 51(6):21-5. · 0.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the study was analysis of dependence of clinical picture and degree of severity of left ventricular hypertrophy (LVH) on polymorphism A/C of ATR1 gene in patients with hypertrophic cardiomyopathy (HCMP) and hypertensive disease (HD). With the method of polymerase chain reaction genotyping for polymorphic markers of A/C of ATR1 gene was carried out in 35 patients with HCMP and 33 patients with LVH developed at the background of long lasting HB. In the work we used clinico-instrumental methods of investigation (electrocardiography - ECG, echocardiography). It was revealed as result of the study that in HCMP type AA in comparison with type AC of ATR1 gene was associated with addition of arterial hypertension, presence of left ventricular outflow tract obstruction, greater severity of heart failure. In case of combination of HD with LVH type AA in comparison with types AC and CC of ATR1 gene is associated with more pronounced LVH.
    Kardiologiia 01/2010; 50(2):41-4. · 0.12 Impact Factor
  • Kardiologiia 02/2008; 48(5):10-5. · 0.12 Impact Factor
  • M D Smirnova · T V Fofanova · A Iu Postnov · F T Ageev
    Terapevticheskii arkhiv 02/2008; 80(1):77-84. · 0.05 Impact Factor